# Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

> **NCT00386633** · PHASE1 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 36 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MVA-mBN32
- **BIOLOGICAL:** MVA-mBN32

## Key facts

- **NCT ID:** NCT00386633
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2015-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386633, "Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00386633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*